Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralymphatic Immunotherapy in Seasonal Allergic Rhinitis
NCT02975479Phase 3Completed
- Sponsor
- Karolinska Institutet
- Start
- May 2016
- Primary completion
- Jun 2022
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ALK Alutard 5-grasses and alutard-sq in seasonal allergic rhinitis (SAR) (2 arms), sponsored by Karolinska Institutet. Primary endpoint: Mean combined daily symptoms-and-medications-score. Started May 2016; status: completed.
02
Drugs
ALK Alutard 5-grassesalutard-sq
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT02975479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02975479.